1
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kohler BA, Ward E, McCarthy BJ, Schymura
MJ, Ries LA, Eheman C, et al: Annual report to the nation on the
status of cancer, 1975–2007, featuring tumors of the brain and
other nervous system. J Natl Cancer Inst. 103:714–736. 2011.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Fisher JL, Schwartzbaum JA, Wrensch M and
Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–890.
2007. View Article : Google Scholar : PubMed/NCBI
|
5
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Cordner R, Black KL and Wheeler CJ:
Exploitation of adaptive evolution in glioma treatment. CNS Oncol.
2:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Smith C and Ironside JW: Diagnosis and
pathogenesis of gliomas. Curr Diagn Pathol. 13:180–192. 2007.
View Article : Google Scholar
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions'. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, et al: MicroRNA expression profiles classify
human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Li M, Li J, Liu L, Li W, Yang Y and Yuan
J: MicroRNA in human glioma. Cancers (Basel). 5:1306–1331. 2013.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Sun B, Pu B, Chu D, Chu X, Li W and Wei D:
MicroRNA-650 expression in glioma is associated with prognosis of
patients. J Neurooncol. 115:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hou SX, Ding BJ, Li HZ, Wang L, Xia F, Du
F, et al: Identification of microRNA-205 as a potential prognostic
indicator for human glioma. J Clin Neurosci. 20:933–937. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Hu E, Wang D, Zhang X, Li J, Hu Y, Gong H,
et al: Four common polymorphisms in microRNAs and the risk of adult
glioma in a Chinese case-control study. J Mol Neurosci. 51:933–940.
2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang Q, Li P, Li A, Jiang W, Wang H, Wang
J and Xie K: Plasma specific miRNAs as predictive biomarkers for
diagnosis and prognosis of glioma. J Exp Clin Cancer Res.
31:972012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lavon I: The role of microRNAs in gliomas
and their potential applications for diagnosis and treatmentNovel
Therapeutic Concepts in Targeting Glioma. Farassati F: InTech; pp.
75–88. 2012
|
19
|
Sarkar A and Hochedlinger K: The sox
family of transcription factors: Versatile regulators of stem and
progenitor cell fate. Cell Stem Cell. 12:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Masui S, Nakatake Y, Toyooka Y, Shimosato
D, Yagi R, Takahashi K, et al: Pluripotency governed by Sox2 via
regulation of Oct3/4 expression in mouse embryonic stem cells. Nat
Cell Biol. 9:625–635. 2007. View
Article : Google Scholar : PubMed/NCBI
|
21
|
Liu K, Lin B, Zhao M, Yang X, Chen M, Gao
A, Liu F, Que J and Lan X: The multiple roles for Sox2 in stem cell
maintenance and tumorigenesis. Cell Signal. 25:1264–1271. 2013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
González-Márquez R, Llorente JL, Rodrigo
JP, García-Pedrero JM, Álvarez-Marcos C, Suárez C and Hermsen MA:
SOX2 expression in hypopharyngeal, laryngeal and sinonasal squamous
cell carcinoma. Hum Pathol. 45:851–857. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Qiao B, He B, Cai J and Yang W: The
expression profile of Oct4 and Sox2 in the carcinogenesis of oral
mucosa. Int J Clin Exp Pathol. 7:28–37. 2013.PubMed/NCBI
|
24
|
Huang YH, Luo MH, Ni YB, Tsang JY, Chan
SK, Lui PC, Yu AM, Tan PH and Tse GM: Increased SOX2 expression in
less differentiated breast carcinomas and their lymph node
metastases. Histopathology. 64:494–503. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J
and Chen G: Elevated expression of SOX2 and FGFR1 in correlation
with poor prognosis in patients with small cell lung cancer. Int J
Clin Exp Pathol. 6:2846–2854. 2013.PubMed/NCBI
|
26
|
Chen Y, Huang Y, Huang Y, Chen J, Wang S
and Zhou J: The prognostic value of SOX2 expression in non-small
cell lung cancer: A meta-analysis. PLoS One. 8:e711402013.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Dahlrot RH, Hermansen SK, Hansen S and
Kristensen BW: What is the clinical value of cancer stem cell
markers in gliomas? Int J Clin Exp Pathol. 6:334–348.
2013.PubMed/NCBI
|
28
|
Annovazzi L, Mellai M, Caldera V, Valente
G and Schiffer D: SOX2 expression and amplification in gliomas and
glioma cell lines. Cancer Genomics Proteomics. 8:139–147.
2011.PubMed/NCBI
|
29
|
Schmitz M, Temme A, Senner V, Ebner R,
Schwind S, Stevanovic S, et al: Identification of SOX2 as a novel
glioma-associated antigen and potential target for T cell-based
immunotherapy. Br J Cancer. 96:1293–1301. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Karnofsky DA and Burchenal JH: The
clinical evaluation of chemotherapeutic agents in cancerEvaluation
of Chemotherapeutic Agents. MacLeod CM: Columbia University Press;
New York: pp. 191–205. 1949
|
31
|
Mur P, Mollejo M, Hernández-Iglesias T, de
Lope ÁR, Castresana JS, García JF, et al: Molecular classification
defines 4 prognostically distinct glioma groups irrespective of
diagnosis and grade. J Neuropathol Exp Neurol. 74:241–249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Noda SE, El-Jawahri A, Patel D,
Lautenschlaeger T, Siedow M and Chakravarti A: Molecular advances
of brain tumors in radiation oncology. Semin Radiat Oncol.
19:171–178. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Desjardins A, Rich JN, Quinn JA,
Vredenburgh J, Gururangan S, Sathornsumetee S, et al: Chemotherapy
and novel therapeutic approaches in malignant glioma. Front Biosci.
10:2645–2668. 2005. View
Article : Google Scholar : PubMed/NCBI
|
34
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
35
|
Singh SK, Clarke ID, Hide T and Dirks PB:
Cancer stem cells in nervous system tumors. Oncogene. 23:7267–7273.
2004. View Article : Google Scholar : PubMed/NCBI
|
36
|
Chen J, McKay RM and Parada LF: Malignant
glioma: Lessons from genomics, mouse models and stem cells. Cell.
149:36–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Bier A, Giladi N, Kronfeld N, Lee HK,
Cazacu S, Finniss S, et al: MicroRNA-137 is downregulated in
glioblastoma and inhibits the stemness of glioma stem cells by
targeting RTVP-1. Oncotarget. 4:665–676. 2013.PubMed/NCBI
|
38
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
39
|
Papagiannakopoulos T, Shapiro A and Kosik
KS: MicroRNA-21 targets a network of key tumor-suppressive pathways
in glioblastoma cells. Cancer Res. 68:8164–8172. 2008. View Article : Google Scholar : PubMed/NCBI
|
40
|
Wang Q, Li P, Li A, Jiang W, Wang H, Wang
J and Xie K: Plasma specific miRNAs as predictive biomarkers for
diagnosis and prognosis of glioma. J Exp Clin Cancer Res.
31:972012. View Article : Google Scholar : PubMed/NCBI
|
41
|
Hermansen SK, Dahlrot RH, Nielsen BS,
Hansen S and Kristensen BW: MiR-21 expression in the tumor cell
compartment holds unfavorable prognostic value in gliomas. J
Neurooncol. 111:71–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
42
|
Sasayama T, Nishihara M, Kondoh T, Hosoda
K and Kohmura E: MicroRNA-10b is overexpressed in malignant glioma
and associated with tumor invasive factors, uPAR and RhoC. Int J
Cancer. 125:1407–1413. 2009. View Article : Google Scholar : PubMed/NCBI
|
43
|
Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang
J, et al: MicroRNA-10b induces glioma cell invasion by modulating
MMP-14 and uPAR expression via HOXD10. Brain Res. 1389:9–18. 2011.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Dong CG, Wu WK, Feng SY, Wang XJ, Shao JF
and Qiao J: Co-inhibition of microRNA-10b and microRNA-21 exerts
synergistic inhibition on the proliferation and invasion of human
glioma cells. Int J Oncol. 41:1005–1012. 2012.PubMed/NCBI
|
45
|
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan
X, et al: MicroRNA-128 inhibits glioma cells proliferation by
targeting transcription factor E2F3a. J Mol Med (Berl). 87:43–51.
2009. View Article : Google Scholar : PubMed/NCBI
|
46
|
Godlewski J, Nowicki MO, Bronisz A,
Williams S, Otsuki A, Nuovo G, et al: Targeting of the Bmi-1
oncogene/stem cell renewal factor by microRNA-128 inhibits glioma
proliferation and self-renewal. Cancer Res. 68:9125–9130. 2008.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian
X, et al: MiR-128 inhibits tumor growth and angiogenesis by
targeting p70S6K1. PLoS One. 7:e327092012. View Article : Google Scholar : PubMed/NCBI
|
48
|
Gangemi RM, Griffero F, Marubbi D, Perera
M, Capra MC, Malatesta P, et al: SOX2 silencing in glioblastoma
tumor-initiating cells causes stop of proliferation and loss of
tumorigenicity. Stem Cells. 27:40–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
49
|
Põlajeva J, Swartling FJ, Jiang Y, Singh
U, Pietras K, Uhrbom L, Westermark B and Roswall P: miRNA-21 is
developmentally regulated in mouse brain and is co-expressed with
SOX2 in glioma. BMC Cancer. 12:3782012. View Article : Google Scholar : PubMed/NCBI
|